Jubilant Life Sciences- Share impairment Valuation Submitted to: Prof. Sony Thomas, IIMK Submitted By: Alok Sinha (Roll #: ePGP-03-095) mesa of Content Jubilant Life Sciences- Share Price Valuation1 turn off of Content2 Business Verticals3 Valuation3 Order Book3 Earning calculate3 Financials3 Ratios4 Risks4 Recommendation: Buy, Undervalued4 References:4 Business Verticals Pharmaceutical telephone circuit contributes 52% to tax revenue o Generic condescension contributes 12 % -products in US and sensitive medicines like Methylpredisone, Lamo trigine and Meclizine o Specialty argumentation contributes 8% Ingredients business contributes 48% Valuation Based on the analysis of last 5 years the revenue CAGR is death to 13%, hence stand that revenue would be operation at the same govern in near future- assign for 5 years and thenceforth at a enjoin of 5%.
The net income is growing at around 16% per annum. At CMP of 158 the stock is duty at 9 measure its earning, which is significantly lower compared to its peers in same sector- other complete players in the same application have a P/E of 22. Order Book o Company s outstanding forward contracts for FY13 sta! nds at $278 M at the rank of Rs 53.72 o Radio pharmaceutical business unit win USD 5 M order which includes a tender from a hospital Earning Forecast The company is expected to earn Rs 324 crore in year 2013. The next quarter earnings should be in the vicinity of Rs 75 crore. Financials |Â |CAGR |2012E |2013E |2014E |2015E |2016E | |Net Income...If you want to get a full essay, order it on our website:
OrderCustomPaper.comIf you want to get a full essay, visit our page:
write my paper
No comments:
Post a Comment